NCM
CDTX

Nantahala Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Nantahala Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-77,337
Closed -$1.23M – 126
2023
Q4 		$1.23M Sell
77,337
-49,583
-39% -$796K 0.07% 104
2023
Q3 		$2.39M Sell
126,920
-71,175
-36% -$1.4M 0.2% 84
2023
Q2 		$4.48M Sell
198,095
-38,387
-16% -$902K 0.43% 51
2023
Q1 		$6.01M Buy
236,482
+18,109
+8% +$514K 0.46% 45
2022
Q4 		$3.3M Sell
218,373
-9,587
-4% -$114K 0.21% 64
2022
Q3 		$2.92M Sell
227,960
-12,995
-5% -$179K 0.19% 64
2022
Q2 		$2.35M Sell
240,955
-6,789
-3% -$83.9K 0.12% 80
2022
Q1 		$4.13M Sell
247,744
-15,779
-6% -$268K 0.18% 67
2021
Q4 		$6.69M Buy
+263,523
New +$8.2M 0.24% 73

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Nantahala Capital Management's CDTX Position: Q1 2024 in Review

Nantahala Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2024, closing a stake of 77,337 shares — an estimated $1.23M sold.

Nantahala Capital Management first reported a position in CDTX in Q4 2021 and held it in 9 quarters. The position peaked at $6.69M in Q4 2021. 50 funds tracked by Wall St. Rank hold CDTX as of Q1 2024.

  • Nantahala Capital Management reported no remaining Cidara Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 77,337 Cidara Therapeutics shares in Q1 2024, an estimated $1.23M.
  • Nantahala Capital Management first reported a position in Cidara Therapeutics in Q4 2021 and held it in 9 quarters.
  • Nantahala Capital Management's Cidara Therapeutics position peaked at $6.69M in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2024.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.